April 30 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:
AMYLYX PHARMACEUTICALS ANNOUNCES FIRST PARTICIPANT DOSED IN PIVOTAL PHASE 3 LUCIDITY TRIAL OF AVEXITIDE IN POST-BARIATRIC HYPOGLYCEMIA
AMYLYX PHARMACEUTICALS INC - LUCIDITY TRIAL RECRUITMENT EXPECTED TO COMPLETE IN 2025, WITH TOPLINE DATA IN FIRST HALF OF 2026
AMYLYX PHARMACEUTICALS INC - EXPECTS CASH RUNWAY THROUGH END OF 2026
Source text: ID:nBw27lFBca
Further company coverage: AMLX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.